Company intelligence / Profile preview

IntraPace

San Jose, California, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Commercial

Overview

IntraPace developed the abiliti system, an implantable neuromodulation device for obesity that uses electrical pulses to induce satiety. The system received CE Mark approval in Europe and was compared to adjustable gastric banding in post-market studies. U.S. FDA approval was being pursued but not achieved as of the latest reports. The company is no longer active.

Therapeutic areas: Endocrinology
Modalities: DeviceNeuromodulation deviceImplantable medical device
Industry: Implantable Medical Devices

Drug pipeline

1 asset

abiliti

Commercial

Indications: Obesity

Partnerships

Boston Scientific (investor)Johnson & Johnson Development Corp. (investor)

Beyond the preview

Go deeper on IntraPace.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IntraPace.

Explore the full profile